Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study

PURPOSE: Irinotecan and temozolomide have single-agent activity and schedule-dependent synergy against neuroblastoma. Because protracted administration of intravenous irinotecan is costly and inconvenient, we sought to determine the maximum-tolerated dose (MTD) of oral irinotecan combined with temoz...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Wagner, Lars M., Villablanca, Judith G., Stewart, Clinton F., Crews, Kristine R., Groshen, Susan, Reynolds, C. Patrick, Park, Julie R., Maris, John M., Hawkins, Randall A., Daldrup-Link, Heike E., Jackson, Hollie A., Matthay, Katherine K.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2009
Ämnen:
Original Reports
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2667827/
https://ncbi.nlm.nih.gov/pubmed/19171709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.18.5918
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk